# Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients

Study · id `cardio:ct-nct05167513` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05167513](<https://clinicaltrials.gov/study/NCT05167513>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05167513

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 188 participants.

## Technical summary

Registry record NCT05167513. Allocation not applicable; no masking; primary purpose treatment. Start 2021-01-01 (actual); primary completion 2022-04-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 188 participants (enrolled count; ClinicalTrials.gov record NCT05167513, source copy `cardio:ctgov-nct05167513-2022-05-04`, retrieved 2026-10-26)
- Started: 2021-01-01 (actual) (ClinicalTrials.gov record NCT05167513, source copy `cardio:ctgov-nct05167513-2022-05-04`, retrieved 2026-10-26)
- Primary completion: 2022-04-28 (actual) (ClinicalTrials.gov record NCT05167513, source copy `cardio:ctgov-nct05167513-2022-05-04`, retrieved 2026-10-26)
- Completion: 2022-04-28 (actual) (ClinicalTrials.gov record NCT05167513, source copy `cardio:ctgov-nct05167513-2022-05-04`, retrieved 2026-10-26)
- Countries: Pakistan (ClinicalTrials.gov record NCT05167513, source copy `cardio:ctgov-nct05167513-2022-05-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05167513-2022-05-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients
- Acronym: DQOL
- Condition: Quality of Life
- Condition: Type 2 Diabetes
- Condition: Metformin+Sitagliptin
- Intervention (Drug): Metformin / Sitagliptin Oral Tablet
- Lead sponsor: Getz Pharma
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Getz Pharma (`cardio:org-getz-pharma`)

## Provenance

Content hash: b5aa3e8a7157cd0679e8bf8fdb7b9ec6843e1d470b80740efee0fd7766c822df
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
